Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Julie Westerlin Kjeldsen; Cathrine Lund Lorentzen; Evelina Martinenaite; Eva Ellebaek; Marco Donia; Rikke Boedker Holmstroem; Tobias Wirenfeldt Klausen; Cecilie Oelvang Madsen; Shamaila Munir Ahmed; Stine Emilie Weis-Banke; Morten Orebo Holmström; Helle Westergren Hendel; Eva Ehrnrooth; Mai-Britt Zocca; Ayako Wakatsuki Pedersen; Mads Hald Andersen; Inge Marie Svane

doi:10.1038/s41591-022-01771-w

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Julie Westerlin Kjeldsen, Cathrine Lund Lorentzen, Evelina Martinenaite, Eva Ellebaek, Marco Donia, Rikke Boedker Holmstroem, Tobias Wirenfeldt Klausen, Cecilie Oelvang Madsen, Shamaila Munir Ahmed, Stine Emilie Weis-Banke, Morten Orebo Holmström, Helle Westergren Hendel, Eva Ehrnrooth, Mai-Britt Zocca, Ayako Wakatsuki Pedersen, Mads Hald Andersen, Inge Marie Svane

2 Citations (Scopus)

Original language	English
Publication date	Apr 2022
Edition	4
Volume	28
Number of pages	1
DOIs	https://doi.org/10.1038/s41591-022-01771-w
Publication status	Published - Apr 2022

Series	Nature Medicine
ISSN	1078-8956

Access to Document

10.1038/s41591-022-01771-w

Cite this

Kjeldsen, J. W., Lorentzen, C. L., Martinenaite, E., Ellebaek, E., Donia, M., Holmstroem, R. B., Klausen, T. W., Madsen, C. O., Ahmed, S. M., Weis-Banke, S. E., Holmström, M. O., Hendel, H. W., Ehrnrooth, E., Zocca, M.-B., Pedersen, A. W., Andersen, M. H., & Svane, I. M. (2022, Apr). Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma. (4 ed.) Nature Medicine https://doi.org/10.1038/s41591-022-01771-w

Kjeldsen, JW, Lorentzen, CL, Martinenaite, E , Ellebaek, E , Donia, M , Holmstroem, RB, Klausen, TW, Madsen, CO , Ahmed, SM , Weis-Banke, SE , Holmström, MO , Hendel, HW, Ehrnrooth, E, Zocca, M-B, Pedersen, AW, Andersen, MH & Svane, IM 2022, Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.. https://doi.org/10.1038/s41591-022-01771-w

@misc{dd690b66ea7b4a83952848c8b77ec626,

title = "Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma",

author = "Kjeldsen, {Julie Westerlin} and Lorentzen, {Cathrine Lund} and Evelina Martinenaite and Eva Ellebaek and Marco Donia and Holmstroem, {Rikke Boedker} and Klausen, {Tobias Wirenfeldt} and Madsen, {Cecilie Oelvang} and Ahmed, {Shamaila Munir} and Weis-Banke, {Stine Emilie} and Holmstr{\"o}m, {Morten Orebo} and Hendel, {Helle Westergren} and Eva Ehrnrooth and Mai-Britt Zocca and Pedersen, {Ayako Wakatsuki} and Andersen, {Mads Hald} and Svane, {Inge Marie}",

year = "2022",

month = apr,

doi = "10.1038/s41591-022-01771-w",

language = "English",

volume = "28",

series = "Nature Medicine",

publisher = "Nature Publishing Group",

edition = "4",

type = "Other",

}

TY - GEN

T1 - Author Correction

T2 - A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

AU - Kjeldsen, Julie Westerlin

AU - Lorentzen, Cathrine Lund

AU - Martinenaite, Evelina

AU - Ellebaek, Eva

AU - Donia, Marco

AU - Holmstroem, Rikke Boedker

AU - Klausen, Tobias Wirenfeldt

AU - Madsen, Cecilie Oelvang

AU - Ahmed, Shamaila Munir

AU - Weis-Banke, Stine Emilie

AU - Holmström, Morten Orebo

AU - Hendel, Helle Westergren

AU - Ehrnrooth, Eva

AU - Zocca, Mai-Britt

AU - Pedersen, Ayako Wakatsuki

AU - Andersen, Mads Hald

AU - Svane, Inge Marie

PY - 2022/4

Y1 - 2022/4

UR - http://www.scopus.com/inward/record.url?scp=85125782597&partnerID=8YFLogxK

U2 - 10.1038/s41591-022-01771-w

DO - 10.1038/s41591-022-01771-w

M3 - Other contribution

C2 - 35260843

VL - 28

T3 - Nature Medicine

ER -

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

Access to Document

Other files and links

Cite this